Viktor Drvota

Viktor Drvota Email and Phone Number

Chief Executive Officer @ Umecrine Cognition AB
Stockholm County, Sweden
Viktor Drvota's Location
Stockholm, Stockholm County, Sweden, Sweden
Viktor Drvota's Contact Details

Viktor Drvota personal email

n/a

Viktor Drvota phone numbers

About Viktor Drvota

Venture Capitalist in Pharma/Biotech/Medtech since 2002 with a clinical and academic background as Associate professor/senior consultant in interventional cardiology at Karolinska Institute.Teambuilding philosophy: Hire people that complement you, are smarter than you and then listen to them.Personality: Extrovert, social, credible, trustworthy, thrive under stressLeadership style: Warm, including, supportive, fun, decisive and without prestige

Viktor Drvota's Current Company Details
Umecrine Cognition AB

Umecrine Cognition Ab

View
Chief Executive Officer
Stockholm County, Sweden
Website:
umecrinecognition.com
Employees:
12
Viktor Drvota Work Experience Details
  • Umecrine Cognition Ab
    Chief Executive Officer
    Umecrine Cognition Ab
    Stockholm County, Sweden
    View
  • Karolinska Development
    Ceo
    Karolinska Development Jun 2017 - Present
    Solna, Stockholm County, Se
    CEO of NASDAQ listed early stage life science venture capital company. Chairman and/or BoD executive in both private and listed biotech and medtech portfolio companies.Managed convertible loan set off of 484 MSEK in 2019Managed right issue of 378 MSEK in 2022Other companies except for the companies below that I am/was indirectly involved in: Anacardio, PharmNovo, Henlez, Pharmanest/Palette.Other managed exits at KD: BioArctic, Lipidor, X Spray Pharma, Pharmanest, Asarina pharma ,ISS ,partial exits in Aprea and Ossdsign.Between 2016 to Q2 2023, KD managed portfolio companies have raised 4120 MSEK whereof KD have invested 540 MSEK. in this timeperiod KD has so far realised 435 MSEK in exit proceeds over 10 exits or partial exits and 9 companies have gone public
    View
  • Karolinska Development
    Board Member
    Karolinska Development May 2019 - May 2020
    Solna, Stockholm County, Se
    View
  • Kdev Investments Ab
    Board Member / Chairman
    Kdev Investments Ab May 2017 - Present
    Co owned investment company by Rosetta Capital and Karolinska development.Chairman 2018, 2020 and 2022
  • Kcif Fund Management Ab
    Ceo / Board Member
    Kcif Fund Management Ab Mar 2021 - Present
    Investment vehicle co owned by EIF (European investment fund) and Karolinska Development
  • Modus Therapeutics Ab
    Chairman Of The Board Of Directors
    Modus Therapeutics Ab Oct 2016 - Present
    Modus Therapeutics – A listed Swedish drug development company in clinical phase focused on sepsis, anemia in kidney disease and malaria.The company is entering phase IIVC round with HealtCap as lead investor in 2018IPO 2021
  • Umecrine Cognition Ab
    Chairman Of The Board Of Directors
    Umecrine Cognition Ab Mar 2016 - Present
    Umecrine Cognition is a private company developing pharmaceuticals against neurological disorders in the central nervous system, CNS that are caused by endogenous CNS-active steroids (GABA-steroids). The company is focused on the development and commercialization of novel therapeutics to treat cognitive disorders and neuroinflammation in primary biliary cholangitis (PBC) and Parkinson disease.The company have statistically significant results in phase IIa and is now conducting a phase IIb study in PBC.
  • Dilafor Ab
    Chairman / Board Member
    Dilafor Ab Mar 2016 - Present
    Dilafor is a private pharma company developing Tafoxiparin in labour induction and preeclampsia. A phase IIb study in labor induction showed statistically significant dose response effect and the company is preparing for phase III.Several VC rounds with Rosetta capital, Östersjöstiftelsen, Praktikertjänst invest, Opocrin spa. Lee Pharamceuticals and KDAn open label study in preeclampsia is recruiting.
  • Ossdsign Ab
    Board Member / Chairman
    Ossdsign Ab Nov 2015 - Present
    Uppsala, Uppsala County, Se
    Medical device company developing and selling nanosythetic bone grafts and 3D implants with innovative ceramic material for cranial use.Commercial stage with distributors/ own organisation in US and EUIPO 2019. The company have raised approx. 1 bn SEK since inception in 2011Chairman 2015 11 - 2016 05
    View
  • Svf Vaccines Ab
    Deputy Board Member
    Svf Vaccines Ab Oct 2020 - Present
    Stockholm, Stockholm, Se
    Managed a university spin out from Karolinska Institute. The company is developing a curative immunotherapy for hepatitis B and D which is in preclinical stage.A Covid19 vaccine is in phase I and is being developed as PoC for the platform
    View
  • Forendo Pharma Ltd
    Board Member
    Forendo Pharma Ltd Sep 2017 - Dec 2021
    Company within Womens health (endometriosis and PCOS). Several VC rounds with Novo seeds, Novartis venture fund, Vesalius, Sunstone, Merck ventures, Innovestor and KD.Sold to Organon 2021 for a total deal value of 950 MUSD
  • Aprea Therapeutics Ab
    Board Member
    Aprea Therapeutics Ab Apr 2017 - Apr 2019
    Aprea Therapeutics is a Stockholm, Sweden and Boston, Massachusetts-based biopharmaceutical company focused on the discovery and development of novel anticancer compounds In March 2016, Aprea completed a EUR 46 million Series B financing with an international syndicate co-led by Versant Ventures and 5AM Ventures, with additional participation by Sectoral Asset Management, HealthCap, acting as local lead investor, and existing investor, Karolinska Development.PreIPO round of 50 MUSD with US crossover investorsIPO NASDAQ US 2019
  • Promimic Ab
    Board Member / Chairman
    Promimic Ab Apr 2016 - Apr 2018
    Medical device company developing and selling the HA Nano surface for coating of dental and orthopedic implants in order to create better osseointegration.Several deals done for example with S.I.N and Danco anodizing.Chairman 2016 07 - 2017 03IPO 2022Commercial stage
  • Karolinska Development Ab
    Chief Investment Officer
    Karolinska Development Ab Feb 2016 - May 2017
  • Clanotech Ab
    Board Member
    Clanotech Ab Mar 2016 - Jul 2016
    Clanotech is an ophthalmology company in preclinical phase with a lead candidate that is an inhibitor of the alpha5beta1-integrin receptor. Asset sold to Rosetta capital
    View
  • Index Diagnostics Ab
    Board Member / Chairman
    Index Diagnostics Ab Jun 2011 - Jul 2016
    The company developed commercialized a diagnostic test to differ between Chrons disease and Ulcerative colitisChairman 2013 -2016
  • Akinion Ab
    Member Of The Board
    Akinion Ab Feb 2016 - Jun 2016
    Biotechnology company developing AKN-028, a dual mechanism inhibitor of the oncogenic FMS-like tyrosine kinase-3 (FLT3) receptor and a downstream DNA repair target for the treatment of acute myeloid leukemia (AML). Assets sold to Accelerated innovations
  • Index Pharmaceuticals Ab
    Board Member
    Index Pharmaceuticals Ab Aug 2003 - Jun 2016
    Solna, Stockholm County, Se
    Biotechnology company developing a DNA immune modulatory drug with TLR -9 as a target in ulcerative colitis. Phase III in ulcerative colitis underwayIPO 2016 after several VC rounds with Neomed, Industrifonden and Linc
    View
  • Avidicare
    Board Member / Chairman
    Avidicare Jul 2012 - Jan 2016
    Lund, Se
    A med tech company developing and selling an innovative ventilation technology for better infection control in operating theaters.Chairman 2010 11 - 2012 01 and 2012 09 . 2013 09Several VC rounds with SEB ventures and IndustrifondenCommercial stage EU
    View
  • Nuevolution
    Board Memeber
    Nuevolution Jul 2007 - Jan 2016
    Nuevolution was a Scandinavian biopharmaceutical company focused on developing drug treatments for human diseases within oncology and chronic inflammatory diseases. Nuevolution is the inventor of Chemetics®, a patent protected drug discovery platform, which enables efficient discovery of novel small molecule (tablet based) drug candidates. The platform provides access to screening of billions of molecules and efficient optimization of drug properties in the process of identifying the drug candidate. Chemetics® has been successfully applied in numerous drug discovery and technology licensing partnerships against tough-to-drug biological disease targets, where other approaches had failed.Over the years, Nuevolution has entered 15 agreements with partners including Novartis, Janssen Biotech, Inc. (Johnson & Johnson), Boehringer Ingelheim, GlaxoSmithKline, Merck & Co (MSD), Lexicon Pharmaceuticals, as well as world-class oncology research institutions, such as Cancer Research Technology and Institute of Cancer Research.Several VC rounds with SEB ventures, Sunstone, IndustrifondenIPO in 2015 and sold to Amgen 2019 for 1,6 bSEK
  • Airsonett Ab
    Board Member
    Airsonett Ab Jul 2007 - Jan 2016
    Airsonett is a medtech company developing an allergen avoidance treatment for patients with severe atopic asthma who, in spite of taking asthma medication, still has poorly controlled asthma.Airsonett ensures that the patient sleeps in clean air. Studies show that Airsonett inhibits the allergy, reduces the inflammation and improves quality of life. Several pivotal studies performed before commercialization.Several VC rounds with SEB venture and IndustrifondenCommercial stage EU
    View
  • Scibase Ab
    Board Member / Chairman
    Scibase Ab Jul 2005 - Jan 2016
    SciBase AB is a Swedish medical technology company, headquartered in Stockholm, that has developed a unique point of care device for the accurate detection of malignant melanoma, Keranocyte cancers and skin barrier defects. The technology is based on electrical impedance in combination with AI.The company have done a PMA In USCommercial stage EU and USIPO in 2015 after several VC rounds with SEB venture and Fourrier TransformChairman 2014 01 - 2014 04
  • Seb Vc
    Head Life Science Venture
    Seb Vc Aug 2002 - Jan 2016
    Stockholm, Stockholm, Se
    Portfolio responsibility for life science portfolio at SEB venture capital with 240 M€ in an evergreen fund structure. in 2016, SEB VC have done101 investments and 71 exits since it´s inception in 1995.Multiple investments done / negotiated both in medtech and pharma companies. Large experience from board work in VC backed companies.The companies I was involved in during this time period raised more than 2 billion SEKOther companies except for the companies below that I was involved in: Cresco SA (sold to Astra Tech), Prostalund (sold back to founders), Personal chemistry (Biotage)(IPO Stockholm), LightUp AB (merged with Bactus AB) , X-counter (IPO Aim London), Also serving in the investment commitee of the IT/tech venture part of SEB VCAs part of the management team at SEB VC since 2005 I have been indirectly involved in the following tech Exits among others:Kreatel AB, trade sale to Motorola Inc 2006; Interpeak AB trade sale to Windriver Inc 2006; Carmen systems, trade sale to Boeing Inc 2006; Spotfire Inc, trade sale to Tibco Inc 2007; Zealcore AB, trade sale to Enea AB 2008; TimeCare AB, trade sale to Allocate software 2009, 3Nine AB, trade sale to Sagri development AB 2010; Ascade holding AB trade sale to CSG International 2012, Tail-F to Cisco 2014.
    View
  • Neoventa Medical
    Board Member
    Neoventa Medical Jan 2005 - Aug 2015
    Mölndal, Se
    Neoventa is a medical device company developing a fetal monitoring device. Performed several large (5000 + patients) clinical studies before commercialization.Several VC rounds with Investor growth capital, HealthCap and SEB venturesPMA in US doneCommercial stage EU
    View
  • Quickcool
    Board Member
    Quickcool Apr 2007 - Apr 2012
    Quickcool devloped an intranasal cooling device for cardiac arrest patientsSeveral VC rounds with CapMan and SEB ventureSold back to founders
  • Sanos A/S
    Board Member
    Sanos A/S Jun 2005 - Jun 2010
    Developed a GLP-2 agonist for Osteoporosis through phase II. Several VC rounds with SLS venture and SEB ventureSold to Nordic Biotech A/S
  • Sbl Vaccin Ab
    Board Member
    Sbl Vaccin Ab May 2004 - Nov 2006
    Vaccine company with a proprietary vaccin for Cholera and a major vaccin distributor in Scandinavia. Management buy out with 3i and SEB ventureSold to Crucell in 2006
  • Phasein Ab
    Deputy Board Member
    Phasein Ab Nov 2002 - Sep 2006
    Medical device company developing sensors anestethic gases as well as Oxygen and CO2.Sold to Masimo Inc
  • Quiatech Ab
    Board Member
    Quiatech Ab May 2003 - May 2006
    Research tool company within oligonucleotide synthesis, DNA micro arrays, in vitro diagnostics and molecular analysis. Several VC rounds with Industrifonden and SLS venturesSold back to founder sin 2006
  • Arexis Ab
    Board Member
    Arexis Ab Oct 2002 - Aug 2005
    Pharmaceutical company who developed a drug for fat malabsorption in CF and neonates through phase II. Several VC rounds with 3i, Industrifonden and SEB venturesSold to SOBI in 2005
  • Karolinska Hospital, Karolinska Institute, Stockholm County, Sweden
    Associate Professor Cardiology
    Karolinska Hospital, Karolinska Institute, Stockholm County, Sweden Jan 1991 - Aug 2002
    - Associate professor of cardiology (interventional cardiologist) / Senior consultant- 33 Published articles in peer reviewed journals with a mean impact factor of 3.9 (1.2 - 29.5)- Tutored three PhD students- PhD thesis 1997: Molecular Pharmacology of Amiodarone (research in an industry collaboration with pharmaceutical company KaroBio focusing on thyroid hormone receptor as an antiarrhythmic concept)- Together with Prof. Christer Sylvén responsible for (and founded) the Cardiac Molecular Laboratory at NOVUM research center, Karolinska Institute 1996 – 2002. We focused on gene therapy with VEGF in refractory angina pectoris patients (part of multinational placebo controlled trial, Euroinject) and stemcell therapies.- Extensive academic teaching experience

Viktor Drvota Skills

Lifesciences Venture Capital Clinical Development Life Sciences Commercialization Drug Discovery Biotechnology Clinical Research Cardiology Healthcare Pharmaceutical Industry Business Strategy Clinical Trials Mergers And Acquisitions Neuroscience Science Medical Devices Drug Development Portfolio Management Medical Education Biopharmaceuticals Immunology Cro Infectious Diseases Molecular Biology Oncology Hardware Diagnostics Medical Affairs Board Certified Technology Transfer Cancer Clinical Health Cardiac

Viktor Drvota Education Details

  • Karolinska Institutet
    Karolinska Institutet
    Medicine
  • Kth Royal Institute Of Technology
    Kth Royal Institute Of Technology
    Business And Administration
  • Karolinska Institutet
    Karolinska Institutet
    Cardiology
  • Karolinska Institutet
    Karolinska Institutet
    Interventional Cardiology Residency Program
  • Karolinska Institutet
    Karolinska Institutet
    Internal Medicine
  • Karolinska Institutet
    Karolinska Institutet
    Doctor Of Medicine - Md

Frequently Asked Questions about Viktor Drvota

What company does Viktor Drvota work for?

Viktor Drvota works for Umecrine Cognition Ab

What is Viktor Drvota's role at the current company?

Viktor Drvota's current role is Chief Executive Officer.

What is Viktor Drvota's email address?

Viktor Drvota's email address is viktor.drvota@seb.se

What is Viktor Drvota's direct phone number?

Viktor Drvota's direct phone number is +468524*****

What schools did Viktor Drvota attend?

Viktor Drvota attended Karolinska Institutet, Kth Royal Institute Of Technology, Karolinska Institutet, Karolinska Institutet, Karolinska Institutet, Karolinska Institutet.

What skills is Viktor Drvota known for?

Viktor Drvota has skills like Lifesciences, Venture Capital, Clinical Development, Life Sciences, Commercialization, Drug Discovery, Biotechnology, Clinical Research, Cardiology, Healthcare, Pharmaceutical Industry, Business Strategy.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.